The European Commission Approves Samsca(TM) (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Tokyo, Japan and Uxbridge, England (ots/PRNewswire) - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that the European Commission has approved the Marketing Authorisation Application for the company's oral once-daily medication Samsca(TM)(tolvaptan), a selective ...
mehr